Advancing RWE together with academia

  The promise of real-world Evidence (RWE) to offer a cost-effective way to help drive transformations in healthcare and drug development is dependent on significant improvements being made in the way real-world data (RWD) is collected and developed into robust evidence.  Challenges include limited access to databases, incomplete data and problems dealing with the enormous volume of data generated on a daily basis. Much time is spent on acquisition, cleansing, integration, standardisation and encryption, as well as analysis and extraction of insights.  This is where closer collaboration between pharma and academia can help. The two can do a lot more to foster stronger ties and more fruitful cross-sector collaborations, says Thomas D ’Hooghe VP and head of global medical affairs fertility at Merck KGaA.   With 20 years of medical scientific experience in academia, he has worked on projects ranging from from pre-clinical research in animal models, to diagnostics and real-world data to health economics and patient-centricity projects.   Differing incentives Pharma needs deep therapeutic area expertise from people who have both a clinical and a medical scientific background, says D ’Hooghe. But the differing drivers that exist between academia and industry are a problem, he says.  “In academia the incentive is really to have new developments, to focus on innovation and to have a paper with a high hit-back factor which creates new grants, new insights and so fo...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news